TCR2 Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner TANG KEVIN C
Feb 14 17:29 ET
TCR2 Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-TANG CAPITAL PARTNERS, LP(0%),TANG CAPITAL MANAGEMENT, LLC(0%), etc.
Feb 14 16:03 ET
TCR2 Therapeutics | 15-12G: Notice of termination of registration of a class of securities under Section 12(g) (and amendment thereto)
Jun 12, 2023 07:00 ET
TCR2 Therapeutics | EFFECT: Others
Jun 6, 2023 00:15 ET
TCR2 Therapeutics | EFFECT: Others
Jun 6, 2023 00:15 ET
TCR2 Therapeutics | EFFECT: Others
Jun 6, 2023 00:15 ET
TCR2 Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner UBS Oncology Impact Fund L.P.
Jun 5, 2023 16:37 ET
TCR2 Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner MPM SunStates Fund, L.P.
Jun 5, 2023 16:36 ET
TCR2 Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner MPM BioVentures 2014, L.P.
Jun 5, 2023 16:36 ET
TCR2 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director GADICKE ANSBERT
Jun 5, 2023 16:35 ET
TCR2 Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Jun 1, 2023 16:45 ET
TCR2 Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Jun 1, 2023 16:44 ET
TCR2 Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Jun 1, 2023 16:43 ET
TCR2 Therapeutics | S-8 POS: S-8 POS
Jun 1, 2023 16:41 ET
TCR2 Therapeutics | S-8 POS: S-8 POS
Jun 1, 2023 16:41 ET
TCR2 Therapeutics | S-8 POS: S-8 POS
Jun 1, 2023 16:40 ET
TCR2 Therapeutics | S-8 POS: S-8 POS
Jun 1, 2023 16:39 ET
TCR2 Therapeutics | S-8 POS: S-8 POS
Jun 1, 2023 16:38 ET
TCR2 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Allen Andrew R
Jun 1, 2023 16:33 ET
TCR2 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Tomasello Shawn
Jun 1, 2023 16:32 ET
No Data
No Data